ArticleNature communications2014
Environment-responsive nanophores for therapy and treatment monitoring via molecular MRI quenching.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 107 citations in OpenAlex.
- Enhancing Tumor Perfusion and Nanomedicine Delivery by Modulating Vascular Tone with Methyl Palmitate Nanoparticles.ACS nano · 2026Article
- Development of Receptor-Integrated Magnetically Labeled Liposomes for Investigating SARS-CoV-2 Fusion Interactions.Analytical chemistry · 2025Article
- New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics.Nature reviews. Materials · 2023Article
- Iron oxide nanoparticles trigger endoplasmic reticulum damage in steatotic hepatic cells.Nanoscale advances · 2023Article
- Simultaneous quantitative imaging of two PET radiotracers via the detection of positron-electron annihilation and prompt gamma emissions.Nature biomedical engineering · 2023Article
- Translatable Drug-Loaded Iron Oxide Nanophore Sensitizes Murine Melanoma Tumors to Monoclonal Antibody Immunotherapy.ACS nano · 2023Article
- Endowing improved osteogenic activities with collagen membrane by incorporating biocompatible iron oxide nanoparticles.Frontiers in bioengineering and biotechnology · 2023Article
- Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.Theranostics · 2022Review
- Ex Vivo and In Vivo Evaluation of Dodecaborate-Based Clusters Encapsulated in Ferumoxytol Nanoparticles.Langmuir : the ACS journal of surfaces and colloids · 2021Article
- Magnetic Nanoparticles Used in Oncology.Materials (Basel, Switzerland) · 2021Review
- A Bimodal Nanosensor for Probing Influenza Fusion Protein Activity Using Magnetic Relaxation.ACS sensors · 2021Article
- Intraoperative assessment and postsurgical treatment of prostate cancer tumors using tumor-targeted nanoprobes.Nanotheranostics · 2021Article
- Sodium Cholate Bile Acid-Stabilized Ferumoxytol-Doxorubicin-Lipiodol Emulsion for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.Journal of vascular and interventional radiology : JVIR · 2020Article
- Pro-organic radical contrast agents ("pro-ORCAs") for real-time MRI of pro-drug activation in biological systems.Polymer chemistry · 2020Article
- Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.ACS nano · 2020Article
- Emerging agents that target signaling pathways in cancer stem cells.Journal of hematology & oncology · 2020Review
- [TNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Review
- Recent Developments in Pathological pH-Responsive Polymeric Nanobiosensors for Cancer Theranostics.Frontiers in bioengineering and biotechnology · 2020Review
- Magnetic Nanoparticles Supporting Bio-responsiveMaterials (Basel, Switzerland) · 2019Review
- Feraheme (Ferumoxytol) Is Recognized by Proinflammatory and Anti-inflammatory Macrophages via Scavenger Receptor Type AI/II.Molecular pharmaceutics · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
The effective delivery of therapeutics to disease sites significantly contributes to drug efficacy, toxicity and clearance. Here we demonstrate that clinically approved iron oxide nanoparticles (Ferumoxytol) can be utilized to carry one or multiple drugs. These so called 'nanophores' retain their cargo within their polymeric coating through weak electrostatic interactions and release it in slightly acidic conditions (pH 6.8 and below). The loading of drugs increases the nanophores' transverse T2 and longitudinal T1 nuclear magnetic resonance (NMR) proton relaxation times, which is proportional to amount of carried cargo. Chemotherapy with translational nanophores is more effective than the free drug in vitro and in vivo, without subjecting the drugs or the carrier nanoparticle to any chemical modification. Evaluation of cargo incorporation and payload levels in vitro and in vivo can be assessed via benchtop magnetic relaxometers, common NMR instruments or magnetic resonance imaging scanners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.